What Is Coherus Oncology, Inc. (CHRS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Coherus Oncology, Inc.'s intrinsic value is estimated at $2.38, presenting a divided outlook at the current price of $1.44. With an average implied return of +65.2% across a split 5–5 (bull–bear) consensus, the model spread of +467.1% underscores analytical uncertainty. Notably, EROIC sees the most upside at +400.1% (fair value: $7.20), while ML-RIV is the most conservative at -67.1% ($0.47). The spread between these extremes — +467.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CHRS?
10 of 13 models are currently active for CHRS. Of these, 5 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates CHRS's intrinsic value at $0.71, implying -50.6% downside from the current price. See which stocks rank higher →
How Does CHRS Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, CHRS ranks #38 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Coherus Oncology, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is CHRS a Value Trap?
CirclFi's Value Trap algorithm assigns CHRS a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Coherus Oncology, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Coherus Oncology, Inc. scores 6.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +467.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CHRS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CHRS's 10 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad